Can a patient with known cardiovascular disease (e.g., coronary artery disease, cerebrovascular disease, peripheral vascular disease, or uncontrolled hypertension) be safely treated with sumatriptan for migraine?

Sumatriptan in Cardiovascular Disease: Contraindicated

Sumatriptan is contraindicated in patients with established cardiovascular disease, including coronary artery disease, cerebrovascular disease, peripheral vascular disease, and uncontrolled hypertension 1. This is an absolute contraindication based on FDA labeling and the risk of serious cardiac events including myocardial infarction, coronary vasospasm, arrhythmias, and stroke.

FDA Contraindications (Absolute)

The FDA label explicitly contraindicates sumatriptan in patients with:

• Ischemic or vasospastic coronary artery disease (including Prinzmetal's angina)
• History of myocardial infarction
• History of stroke or transient ischemic attack (TIA)
• Peripheral vascular disease
• Uncontrolled hypertension 1

Mechanism of Cardiovascular Risk

Sumatriptan causes coronary artery vasospasm through 5-HT1 receptor agonism on coronary vessels, which can precipitate:

• Acute myocardial infarction (even with non-obstructive coronaries) 2
• Life-threatening arrhythmias (ventricular tachycardia, ventricular fibrillation)
• Cerebrovascular events (hemorrhage, stroke)
• Peripheral vascular ischemia 1

Recent case reports document ST-elevation myocardial infarction following sumatriptan use in patients with cardiovascular risk factors 2, and pharmacovigilance data shows sumatriptan carries the highest cardiovascular risk among triptans with the most deaths and serious cases reported 3.

Alternative Approach for Patients with Cardiovascular Disease

For patients with established cardiovascular disease requiring acute migraine treatment:

1. First-line options:

   • NSAIDs (ibuprofen, naproxen) or acetaminophen at adequate doses 4
   • Combination of NSAID + acetaminophen 4

2. Second-line options if NSAIDs fail:

   • CGRP antagonists (gepants): rimegepant, ubrogepant, or zavegepant 4, 5
   • Ditan (lasmiditan): No cardiovascular safety concerns identified and could be used in cardiovascular disease 5

3. Avoid completely:

   • All triptans (contraindicated)
   • Ergot alkaloids (also cause vasospasm)
   • Opioids and butalbital (ineffective and harmful) 4

Critical Caveat for Patients WITHOUT Known CVD

Even in patients without established cardiovascular disease, perform cardiovascular evaluation before prescribing sumatriptan if multiple risk factors are present (age >40, diabetes, hypertension, smoking, obesity, strong family history of CAD) 1. If cardiovascular evaluation is negative but risk factors exist, administer the first dose in a medically supervised setting with immediate ECG monitoring 1.

The Evidence Paradox

While older research suggests triptans may be safer than contraindications suggest 6, 5, and that cardiovascular events are rare, the FDA contraindication remains absolute 1. The 2025 ACP guideline recommends triptans as effective treatment 4, but this applies only to patients without cardiovascular disease. Recent 2024-2025 data continues to document serious cardiovascular events including deaths with sumatriptan use 2, 3.

Bottom line: Do not prescribe sumatriptan to patients with known cardiovascular disease. Use lasmiditan or gepants instead.